Lazard Asset Management
JSPR icon

Lazard Asset Management’s Jasper Therapeutics JSPR Stock Holding History

Lazard Asset Management’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-17
Closed – – 2437
2024
Q4 		$0 Hold
17
– – ﹤0.01% 2407
2024
Q3 		$0 Sell
17
-31
-65% -$617 ﹤0.01% 2366
2024
Q2 		$0 Sell
48
-696
-94% -$16.7K ﹤0.01% 2339
2024
Q1 		$21K Sell
744
-406
-35% -$7.21K ﹤0.01% 1832
2023
Q4 		$8K Buy
1,150
+36
+3% +$242 ﹤0.01% 2103
2023
Q3 		$7K Buy
+1,114
New +$13.6K ﹤0.01% 2162

Other funds holding JSPR

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Lazard Asset Management's JSPR Position: Q1 2025 in Review

Lazard Asset Management sold out of Jasper Therapeutics (JSPR) in Q1 2025, closing a stake of 17 shares.

Lazard Asset Management first reported a position in JSPR in Q3 2023 and held it in 6 quarters. The position peaked at $21K in Q1 2024. 68 funds tracked by Wall St. Rank hold JSPR as of Q1 2025.

  • Lazard Asset Management reported no remaining Jasper Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Lazard Asset Management sold 17 Jasper Therapeutics shares in Q1 2025.
  • Lazard Asset Management first reported a position in Jasper Therapeutics in Q3 2023 and held it in 6 quarters.
  • Lazard Asset Management's Jasper Therapeutics position peaked at $21K in Q1 2024.
  • 68 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2025.

Based on Lazard Asset Management's 13F filing for Q1 2025, filed 15 May 2025.